ESMO shared a post on LinkedIn:
“For ESMO members: Breaking Science in Breast Cancer.
Peter Schmid presents his findings on atezolizumab and sacituzumab govitecan for advanced Triple-negative breast cancer (TNBC).
Explore this video and others from this series on OncologyPRO now.”
Additional information
Source: ESMO/LinkedIn